Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹18,157 Cr
Revenue (TTM)
₹3,078 Cr
Net Profit (TTM)
₹432 Cr
ROE
13.8 %
ROCE
13.6 %
P/E Ratio
42.1
P/B Ratio
5
Industry P/E
28.7
EV/EBITDA
18.4
Div. Yield
0.6 %
Debt to Equity
0.9
Book Value
₹261.5
EPS
₹32.6
Face value
1
Shares outstanding
138,542,887
CFO
₹3,656.87 Cr
EBITDA
₹4,620.48 Cr
Net Profit
₹3,170.97 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Eris Lifesciences
| -13.1 | -2.0 | -16.4 | 3.6 | 32.0 | 16.9 | -- |
|
BSE Healthcare
| -1.7 | -1.1 | -1.9 | 7.5 | 25.6 | 15.6 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Eris Lifesciences
| 13.1 | 51.7 | 40.6 | -14.8 | 28.8 | 16.8 | -31.5 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Eris Lifesciences
|
1,308.1 | 18,156.7 | 3,078.2 | 469.4 | 26.4 | 14.9 | 42.1 | 5.0 |
| 3,056.6 | 38,176.6 | 5,201.6 | 1,014.6 | 22.9 | 25 | 37.6 | 8.3 | |
| 8,483.5 | 21,239.3 | 2,177.5 | 200.9 | 11.3 | 26.5 | 105.7 | 25.5 | |
| 1,648.2 | 12,536.2 | 2,089.5 | 622.0 | 31.3 | 20.4 | 20.4 | 3.8 | |
| 2,118.0 | 33,968.6 | 4,193.0 | 753.8 | 22.7 | 20.8 | 45.1 | 8.5 | |
| 4,818.0 | 22,063.4 | 2,482.3 | 853.6 | 33.7 | 18.9 | 25.8 | 5.5 | |
| 4,939.8 | 8,194.5 | 1,348.5 | 293.5 | 28.1 | 50.7 | 27.9 | 11.8 | |
| 3,460.8 | 7,974.5 | 1,837.4 | 326.7 | 24.7 | 45.3 | 24.4 | 10.6 | |
| 324.6 | 6,348.6 | 1,432.0 | 149.0 | 19.1 | 7.9 | 42.3 | 2.5 | |
| 907.1 | 8,342.6 | 4,725.6 | 528.7 | 14.9 | 20.7 | 16.3 | 2.8 |
Eris Lifesciences Limited, together with its subsidiaries, engages in the manufacture, marketing, and distribution of domestic branded formulations for chronic and sub-chronic therapies in India. The company offers various branded formulations in... various therapeutic areas, such as anti"diabetes, anti-infective, blood related, cardiovascular, dermatology, gastrointestinal, gastroenterology, haematinics, hormones, nero/ central nervous system, neuropsychiatry, otologicals, pain/analgesics, respiratory, stomatologicals, cosmetology, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and ante-natal care solutions. The company offers its products through wholesale drug distributors, and stockiest and retail pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India. Read more
Incorporated
2007
Chairman
Amit Indubhushan Bakshi
Managing Director
Amit Indubhushan Bakshi
Headquarters
Ahmedabad, Gujarat
Website
Looking for more details about Eris Lifesciences Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The share price of Eris Lifesciences Ltd is ₹1,308.10 (NSE) and ₹1,310.55 (BSE) as of 18-Mar-2026 IST. Eris Lifesciences Ltd has given a return of 31.99% in the last 3 years.
The P/E ratio of Eris Lifesciences Ltd is 42.05 times as on 18-Mar-2026, a 47 premium to its peers’ median range of 28.70 times.
The P/B ratio of Eris Lifesciences Ltd is 5.01 times as on 18-Mar-2026, a 10 premium to its peers’ median range of 4.57 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
54.83
|
6.78
|
|
2024
|
29.18
|
4.43
|
|
2023
|
20.36
|
3.55
|
|
2022
|
23.06
|
4.91
|
|
2021
|
23.11
|
5.22
|
The 52-week high and low of Eris Lifesciences Ltd are Rs 1,910.00 and Rs 1,097.20 as of 19-Mar-2026.
Eris Lifesciences Ltd has a market capitalisation of ₹ 18,157 Cr as on 18-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Eris Lifesciences Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹27.70
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.